| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C215-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-094
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B59-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C215-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate |
2008-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2011-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2011502986-A |
| titleOfInvention |
Deuterated fingolimod |
| abstract |
An object of the present invention is to provide a novel compound which is a deuterated derivative of fingolimod and a pharmaceutically acceptable salt thereof. The present invention relates to novel compounds which are deuterated derivatives of fingolimod and pharmaceutically acceptable salts thereof. The invention also includes compositions comprising one or more compounds of the invention and a carrier, and methods of treating diseases and conditions that are beneficially treated by administering a lysophospholipid edg1 (S1P1) receptor agonist such as fingolimod. Provides the use of the disclosed compounds and compositions. [Selection figure] None |
| priorityDate |
2007-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |